Incidence of Diabetic Ketoacidosis among Patients with Type 2 Diabetes Mellitus Treated with SGLT2 inhibitors and Other Antihyperglycemic Agents

• Published in: Diabetes research and clinical practice Vol. 128; pp. 83 - 90
• Main Authors: Wang, Yiting, Desai, Mehul, Ryan, Patrick B, DeFalco, Frank J, Schuemie, Martijn J, Stang, Paul E, Berlin, Jesse A, Yuan, Zhong
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.06.2017
• Subjects: Cohort Studies; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Ketoacidosis - epidemiology; Endocrinology & Metabolism; Female; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Incidence; Ketoacidosis; Male; Middle Aged; Retrospective Studies; Sodium glucose co-transporter 2 (SGLT2) inhibitors; Sodium-Glucose Transporter 2 - antagonists & inhibitors; Type 2 diabetes mellitus; type 2 diabetes mellitus; sodium glucose co-transporter 2 (SGLT2) inhibitors; ketoacidosis; Ketoacidosis; Sodium glucose co-transporter 2 (SGLT2) inhibitors; Type 2 diabetes mellitus
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2017.04.004

Highlights • The overall, unadjusted incidence rates of diabetic ketoacidosis (DKA) were similar between new users of SGLT2 inhibitors and new users of non-SGLT2 antihyperglycemic agents (AHAs). • The overall, unadjusted DKA incidence rates decreased by about 50% when the refined definition of type 2 diabetes was used, which excluded potential autoimmune diabetes. • No statistically significant increased risk for DKA was found in the primary analysis comparing new users of SGLT2 inhibitors with new users of non-SGLT2 AHAs under the broad definition of type 2 diabetes, and under the refined definition that excluded potential autoimmune diabetes. • Fewer than half of the DKA cases identified under the broad definition of type 2 diabetes met the refined definition that excluded potential autoimmune diabetes.